Skip to main content Skip to footer

AGILE trial reports on antiviral activity of molnupiravir in vaccinated and unvaccinated individuals infected with contemporaneous variants of SARS-CoV-2

By

The antiviral drug molnupiravir received regulatory approval for treating people … Continued

First antiviral pill to treat Covid-19 approved in UK

By

A “game-changing” antiviral pill that is part of the AGILE … Continued

AGILE Covid-19 drug testing platform opens new trial in South Africa

By

A new international trial to assess whether high doses of … Continued

First patient dosed in latest stage of AGILE COVID-19 drug trial

By

LIVERPOOL, England, 20 April 2021 — The University of Liverpool, Liverpool School of Tropical Medicine, and the NIHR Southampton Clinical Trials Unit at the University of Southampton today announced the first-ever patient dosed in the latest trial of potential new treatments for SARS-CoV-2 as part of the UK’s COVID-19 drug testing platform, AGILE.

Case study from @Medidata

By

Take a look at this case study from @Medidata who are supporting @SouthamptonCTU with the AGILE clinical trial platform #COVID19 #clinicaltrials

Covid-19 Drug interactions

By

The Liverpool Drug Interactions website team developed a freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.

Find out more here.